Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients: Considerations on the Clinical Picture
Revista Unimontes Científica · 2021
DOI: 10.46551/ruc.v22n2a02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Revista Unimontes Científica, 2021. Verfasst von Marileia Andrade und 1 weiteren Autor:innen.
Themen: Medikationssicherheit
Abstract (Originalsprache)
Since the beginning of the Coronavirus Disease 2019 (COVID-19) pandemic, the most severe symptoms have occurred in elderly patients with comorbidities, with a higher risk of complications. Prescribed drugs, which are already part of geriatric care, associated with the experimental therapeutic drugs of COVID-19, may increase the risk of undesirable occurrences, due to the practice of polypharmacy, with the possibility of emergence of inappropriate adverse events and drug interactions. This can increase the risk of worsening the clinical picture, impairment of the general condition, intensification of inflammation and associated unfavorable conditions, incurring the highest probability of mortality.
Zitieren
APA
Andrade, M., & Pinto, J. H. P. (2021). Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients: Considerations on the Clinical Picture. Revista Unimontes Científica. https://doi.org/10.46551/ruc.v22n2a02
Vancouver
Andrade M, Pinto JHP. Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients: Considerations on the Clinical Picture. Revista Unimontes Científica. 2021. doi:10.46551/ruc.v22n2a02
BibTeX
@article{Andrade2021,
author = {Andrade, Marileia and Pinto, José Henrique Pereira},
title = {Polypharmacy, Adverse Drug Reactions and Drug-Drug Interactions in COVID-19-Aging Patients: Considerations on the Clinical Picture},
journal = {Revista Unimontes Científica},
year = {2021},
doi = {10.46551/ruc.v22n2a02}
}
EUVIMED